CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19(+) Relapsed/Refractory Malignancies

We evaluated the administration of ARI-0001 cells (chimeric antigen receptor T cells targeting CD19) in adult and pediatric patients with relapsed/refractory CD19(+) malignancies. Patients received cyclophosphamide and fludarabine followed by ARI-0001 cells at a dose of 0.4–5 × 10(6) ARI-0001 cells/...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Ther
Autors principals: Ortíz-Maldonado, Valentín, Rives, Susana, Castellà, Maria, Alonso-Saladrigues, Anna, Benítez-Ribas, Daniel, Caballero-Baños, Miguel, Baumann, Tycho, Cid, Joan, Garcia-Rey, Enric, Llanos, Cristina, Torrebadell, Montserrat, Villamor, Neus, Giné, Eva, Díaz-Beyá, Marina, Guardia, Laia, Montoro, Mercedes, Català, Albert, Faura, Anna, González, E. Azucena, Español-Rego, Marta, Klein-González, Nela, Alsina, Laia, Castro, Pedro, Jordan, Iolanda, Fernández, Sara, Ramos, Federico, Suñé, Guillermo, Perpiñá, Unai, Canals, Josep M., Lozano, Miquel, Trias, Esteve, Scalise, Andrea, Varea, Sara, Sáez-Peñataro, Joaquín, Torres, Ferran, Calvo, Gonzalo, Esteve, Jordi, Urbano-Ispizua, Álvaro, Juan, Manel, Delgado, Julio
Format: Artigo
Idioma:Inglês
Publicat: American Society of Gene & Cell Therapy 2021
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7854276/
https://ncbi.nlm.nih.gov/pubmed/33010231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2020.09.027
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars